» Articles » PMID: 24465639

Detection of Colorectal Serrated Polyps by Stool DNA Testing: Comparison with Fecal Immunochemical Testing for Occult Blood (FIT)

Overview
Journal PLoS One
Date 2014 Jan 28
PMID 24465639
Citations 43
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: Precursors to 1/3 of colorectal cancer (CRC), serrated polyps have been under-detected by screening due to their inconspicuous, non-hemorrhagic, and proximal nature. A new multi-target stool DNA test (multi-target sDNA) shows high sensitivity for both CRC and advanced adenomas. Screen detection of serrated polyps by this approach requires further validation. We sought to assess and compare noninvasive detection of sessile serrated polyps (SSP) ≥ 1 cm by sDNA and an occult blood fecal immunochemical test (FIT).

Methods: In a blinded prospective study, a single stool sample used for both tests was collected from 456 asymptomatic adults prior to screening or surveillance colonoscopy (criterion standard). All 29 patients with SSP ≥ 1 cm were included as cases and all 232 with no neoplastic findings as controls. Buffered stool samples were processed and frozen on receipt; Exact Sciences performed sDNA in batches using optimized analytical methods. The sDNA multi-marker panel targets methylated BMP3 (mBMP3) and NDRG4, mutant KRAS, β-actin, and hemoglobin. FIT (Polymedco OC-FIT Check) was performed in separate lab ≤ 2 days post defecation and evaluated at cutoffs of 50 (FIT-50) and 100 ng/ml (FIT-100).

Results: MEDIAN AGES: cases 61 (range 57-77), controls 62 (52-70), p = NS. Women comprised 59% and 51%, p = NS, respectively. SSP median size was 1.2 cm (1-3 cm), 93% were proximal, and 64% had synchronous diminutive polyps. Among multi-target sDNA markers, mBMP3 proved highly discriminant for detection of SSP ≥ 1 cm (AUC = 0.87, p<0.00001); other DNA markers provided no incremental sensitivity. Hemoglobin alone showed no discrimination (AUC = 0.50, p = NS). At matched specificities, detection of SSP ≥ 1 cm by stool mBMP3 was significantly greater than by FIT-50 (66% vs 10%, p = 0.0003) or FIT-100 (63% vs 0%, p<0.0001).

Conclusions: In a screening and surveillance setting, SSP ≥ 1 cm can be detected noninvasively by stool assay of exfoliated DNA markers, especially mBMP3. FIT appears to have no value in SSP detection.

Citing Articles

An investigation of plasma cell-free RNA for the detection of colorectal cancer: From transcriptome marker selection to targeted validation.

Northrop-Albrecht E, Wu C, Berger C, Taylor W, Foote P, Doering K PLoS One. 2024; 19(8):e0308711.

PMID: 39146279 PMC: 11326608. DOI: 10.1371/journal.pone.0308711.


Impact of the Sessile Serrated Polyp Pathway on Predicted Colorectal Cancer Outcomes.

Kisiel J, Itzkowitz S, Ozbay A, Saoud L, Parton M, Lieberman D Gastro Hep Adv. 2024; 1(1):55-62.

PMID: 39129937 PMC: 11307850. DOI: 10.1016/j.gastha.2021.10.007.


Positive Predictive Value for Multitarget Stool DNA After Bariatric and Metabolic Surgery.

Ebner D, Burger K, Broderick B, Mahoney D, Kellogg T, Acosta A Gastro Hep Adv. 2023; 2(7):902-910.

PMID: 37876832 PMC: 10597571. DOI: 10.1016/j.gastha.2023.06.005.


Methylated DNA Markers for Sporadic Colorectal and Endometrial Cancer Are Strongly Associated with Lynch Syndrome Cancers.

Bramblet R, Bakkum-Gamez J, Slettedahl S, Foote P, Taylor W, Berger C Cancer Prev Res (Phila). 2023; 16(11):611-620.

PMID: 37728516 PMC: 10870731. DOI: 10.1158/1940-6207.CAPR-23-0107.


Molecular methods for colorectal cancer screening: Progress with next-generation sequencing evolution.

Abbes S, Baldi S, Sellami H, Amedei A, Keskes L World J Gastrointest Oncol. 2023; 15(3):425-442.

PMID: 37009313 PMC: 10052664. DOI: 10.4251/wjgo.v15.i3.425.


References
1.
Itzkowitz S, Jandorf L, Brand R, Rabeneck L, Schroy 3rd P, Sontag S . Improved fecal DNA test for colorectal cancer screening. Clin Gastroenterol Hepatol. 2006; 5(1):111-7. DOI: 10.1016/j.cgh.2006.10.006. View

2.
Ahlquist D, Sargent D, Loprinzi C, Levin T, Rex D, Ahnen D . Stool DNA and occult blood testing for screen detection of colorectal neoplasia. Ann Intern Med. 2008; 149(7):441-50, W81. PMC: 4016975. DOI: 10.7326/0003-4819-149-7-200810070-00004. View

3.
Park D, Ryu S, Kim Y, Lee S, Lee C, Eun C . Comparison of guaiac-based and quantitative immunochemical fecal occult blood testing in a population at average risk undergoing colorectal cancer screening. Am J Gastroenterol. 2010; 105(9):2017-25. DOI: 10.1038/ajg.2010.179. View

4.
Jass J . Serrated adenoma of the colorectum and the DNA-methylator phenotype. Nat Clin Pract Oncol. 2005; 2(8):398-405. DOI: 10.1038/ncponc0248. View

5.
Fearon E, Vogelstein B . A genetic model for colorectal tumorigenesis. Cell. 1990; 61(5):759-67. DOI: 10.1016/0092-8674(90)90186-i. View